How should trazodone be dosed for insomnia, and what are its contraindications, side effects, and alternative treatments?

Trazodone for Insomnia: Not Recommended as First-Line Treatment

The most recent and highest-quality evidence advises against using trazodone for chronic insomnia disorder. The 2019 VA/DoD guidelines explicitly recommend against trazodone, finding that low-quality evidence of efficacy is outweighed by its adverse effect profile 1.

Why Trazodone Should Not Be First-Line

The evidence hierarchy is clear:

• Trazodone is NOT FDA-approved for insomnia 2
• Efficacy is not well-established for insomnia treatment 2
• The 2020 VA/DoD systematic review found no differences in sleep efficiency or discontinuation rates between trazodone (50-150 mg) and placebo 1
• While trazodone improved subjective sleep quality, it showed no differences in objective measures: sleep onset latency, total sleep time, or wake after sleep onset 1
• Studies were very short duration (mean 1.7 weeks) with only 1-4 weeks follow-up 1

Recommended First-Line Alternatives

Start with these FDA-approved options instead:

First Choice: Non-Benzodiazepine BZRAs

• Zolpidem 10 mg (5 mg in elderly/debilitated) for sleep onset and maintenance 2
• Eszopiclone 2-3 mg (1 mg in elderly) for sleep onset and maintenance 2
• Zaleplon 10 mg (5 mg in elderly) specifically for sleep onset 2

These agents improve sleep efficiency, sleep onset latency, total sleep time, and wake after sleep onset with established efficacy 1.

Second Choice: Melatonin Receptor Agonist

• Ramelteon 8 mg for sleep-onset insomnia 2

Third Choice: Low-Dose Doxepin

• Doxepin 3-6 mg for sleep maintenance insomnia 3

When Trazodone Might Be Considered

Trazodone may be appropriate as a third-line option in specific circumstances 2:

1. Comorbid depression requiring full-dose antidepressant therapy - can add low-dose trazodone as adjunctive sleep aid
2. After failure of BzRAs and ramelteon
3. When combined with another full-dose antidepressant for patients with both depression and insomnia

Dosing When Used (Off-Label)

• Start 50-100 mg at bedtime (based on typical study doses of 50-150 mg) 1
• Take 1 hour before bedtime (not immediately before like hypnotics) 4
• Take shortly after a meal or light snack 5
• Maximum studied doses up to 150 mg 1

Contraindications and Precautions

Absolute Contraindications:

• Current MAOI use or within 14 days of discontinuation 5
• Linezolid or IV methylene blue 5

Use with Extreme Caution in:

• Respiratory compromise (asthma, COPD, sleep apnea) 2
• Hepatic or heart failure 2
• Elderly or debilitated patients (require dose reduction) 2
• Pregnancy or nursing 2
• Patients <18 years (safety not established) 2

Adverse Effects Profile

Common adverse effects that limit use:

• Daytime drowsiness/somnolence (7.34 times more likely than placebo) 6
• Sedation (6.53 times more likely) 6
• Blurred vision (17.50 times more likely) 6
• Decreased appetite 1
• Hypotension, dizziness, nausea 7
• Increased bleeding risk when combined with NSAIDs, antiplatelet agents, or anticoagulants 5

Serious risks:

• Serotonin syndrome (especially with other serotonergic drugs) 5
• Activation of mania/hypomania 5
• Suicidal thoughts (monitor closely, especially early in treatment) 5

Critical Clinical Pitfalls

1. Don't use trazodone as monotherapy for major depression with insomnia - low doses used for sleep are inadequate for treating depression 2

2. Avoid combining with other CNS depressants or alcohol - additive psychomotor impairment 2

3. Don't abruptly discontinue - taper gradually to avoid withdrawal symptoms 5

4. Screen for bipolar disorder before initiating - risk of manic activation 5

5. Adjust dose with CYP3A4 inhibitors/inducers - consider dose reduction with strong inhibitors, increase with strong inducers 5

The Evidence Contradiction

While older 2008 guidelines suggested trazodone as a third-line option after BzRA failure 2, the 2020 VA/DoD guidelines explicitly advise against its use based on systematic review showing insufficient efficacy 1. The 2017 AASM guideline also suggests clinicians not use trazodone for sleep onset or maintenance insomnia 3.

Recent meta-analyses show trazodone may improve sleep architecture (increased N3 deep sleep, decreased awakenings) but with very low quality evidence and significant adverse effects 8, 9. The clinical significance of these polysomnographic changes without improvement in patient-reported total sleep time is questionable 9.

Bottom line: Prioritize FDA-approved hypnotics with established efficacy over trazodone for primary insomnia. Reserve trazodone for specific scenarios where comorbid depression exists or after failure of preferred agents.